Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Chief Executive Officer of CRISPR Therapeutics AG since December 2017 and board member since June 2018. Previously served as President and Chief Business Officer, and Chief Business Officer at CRISPR Therapeutics. Prior experience at McKinsey & Company from 2006 to 2015 as Partner in Pharmaceuticals and Biotechnology practice.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Director

Centessa Pharmaceuticals plc

Jan 1, 2021 – Present

Independence: Independent

Source effective: 2025-05-06 · Observed: 2026-04-28T23:22:01.968+00:00

confirmedView source

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Centessa Pharmaceuticals plc

2021-01-01 · current

Confirmed by public sourceView source

Director

Black Diamond Therapeutics, Inc.

2019-01-01 · current

Confirmed by public sourceView source

Director

CRISPR Therapeutics AG

2018-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Black Diamond Therapeutics, Inc.

Open Black Diamond Therapeutics, Inc. profile →

Director at Black Diamond Therapeutics, Inc.

2019-01-01 → End not stated

current · source reported

Observed: 2026-09-16

Black Diamond Ther…Black Diamond Therapeutics, Inc.Centessa Pharmaceu…Centessa Pharmaceuticals plcCRISPR Therapeutic…CRISPR Therapeutics AGSamarth Kulkarni, …

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingCRSP DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 2 · Sec FilingCNTA DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 3 · Sec FilingBDTX DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:samarth-kulkarni-ph-d
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of Black Diamond Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Centessa Pharmaceuticals plc1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of CRISPR Therapeutics AG1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Lead Independent Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at CRISPR Therapeutics1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Executive company · Source reportedExecutive at CRISPR Therapeutics AG1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · CorroboratedExecutive title: Chief Executive OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources10 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: Board role · Committee assignments

  3. https://www.sec.gov/Archives/edgar/data/1674416/000119312526165158/crsp-20260421.htm

    Sec Proxy · Tier not stated · Reviewed May 3, 2026

    Supports: Director at CRISPR Therapeutics AG (NASDAQ: CRSP)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1847903/000199937125005478/centessa_proxy-2025.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Centessa Pharmaceuticals plc

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  7. https://www.sec.gov/Archives/edgar/data/1701541/000110465925036339/tm252436-4_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Black Diamond Therapeutics, Inc. (NASDAQ: BDTX)

  8. https://www.sec.gov/Archives/edgar/data/1847903/000199937125005478/centessa_proxy-2025.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/1701541/000110465925036339/tm252436-4_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/1674416/000119312526165158/crsp-20260421.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership